Bristol-Myers Squibb Company
Price Action
Technical Summary
CONSOLIDATINGBristol-Myers Squibb Company is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 50), indicating performance broadly in line with the market. Earnings growth of 9% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $56.25 | -2.75% | BELOW |
| 50 SMA | $57.27 | -4.49% | BELOW |
| 100 SMA | $58.38 | -6.30% | BELOW |
| 150 SMA | $56.39 | -3.00% | BELOW |
| 200 SMA | $53.62 | +2.01% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BMY in an uptrend right now?
BMY has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is BMY overbought or oversold?
BMY's RSI (14) is 38. The stock is in neutral territory, neither overbought nor oversold.
Is BMY outperforming the market?
BMY has a Relative Strength (RS) Rating of 50 out of 99. BMY is performing about average compared to the market.
Where is BMY in its 52-week range?
BMY is trading at $54.70, which is 87% of its 52-week high ($62.89) and 60% above its 52-week low ($42.52).
How volatile is BMY?
BMY has a Beta of 0.30 and 52-week volatility of 27%. It's less volatile than the S&P 500 - generally more stable.